Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections

Abstract

Prolonged posaconazole treatment was associated with a generally favorable safety profile in seriously ill patients with refractory invasive fungal infections. Long-term therapy did not increase the risk of any individual adverse event, and no unique adverse event was observed with longer exposure to posaconazole.